A promising new study published online in Cell by NYU Langone Health researchers uncovers a targeted strategy for treating autoimmune diseases such as type 1 diabetes, hepatitis, and multiple sclerosis.
1-2 min read
A promising new study published online in Cell—led by researchers at NYU Langone Health, the Chinese Academy of Sciences, and Zhejiang University—uncovers a targeted strategy for treating autoimmune diseases such as type 1 diabetes, hepatitis, and multiple sclerosis. By engineering a bispecific antibody called the LAG-3/TCR Bispecific T cell Silencer—dubbedBiTS—to bring together the T cell receptor (TCR) and the inhibitory checkpoint protein LAG 3, the research team was able to locally "dial down"harmful T cell activity without suppressing the entire immune system. Tested across three mouse models, BiTS effectively reduced autoimmune tissue damage, from insulitis in diabetes to inflammatory liver disease and multiple sclerosis–like symptoms.
A key pillar of this groundbreaking work was support from NYU Langone’s Judith and Stewart Colton Center for Autoimmunity. This center’s translational advancement award enabled the development of the spatially guided BiTS antibody—highlighting the Colton Center’s mission to catalyze innovative, clinically focused immune therapies. As the first therapeutic approach of its kind to exploit the precise proximity between TCRs and LAG 3, the study not only advances our understanding of immune regulation but also opens the door to a new class of treatments that could safely control overactive immune responses in humans.
For a deeper dive into the science and its implications, read the full article from NYU Langone Health.
.svg)
The Colton Consortium proudly sponsored the 2025 FASEB Autoimmunity Conference in Niagara Falls, a leading international forum advancing autoimmune research and fostering collaboration among scientists and clinicians.
The Colton Center for Autoimmunity at Yale University announced its 2025 award recipients, funding nine translational research projects with nearly $1M to advance diagnostics, treatments, vaccines, and technologies for autoimmune disease.
Penn Medicine’s newly renovated Immune Health facility will house the Penn Colton Center for Autoimmunity—an anchor of the global Colton Consortium—driving bold, cross-disciplinary collaboration to accelerate transformative discoveries in autoimmune disease research.